Patients aged 75 years or older diagnosed with hematologic malignancies appear significantly underrepresented in clinical trials submitted to the U.S. Food and Drug Administration (FDA), according to a retrospective analysis.
At this year's Annual ASH Meeting & Exposition, eight people were recognized as MPN Heroes, and, new this year, a ninth individual was honored as the program’s first Canadian MPN Champion - all for their commitment to the individual and commitment to the broader MPN community.
Prevyis (letermovir) was granted approval by the Food and Drug Administration (FDA) to prevent cytomegalovirus (CMV) infection in adult CMV-seropositive patients treated with an allogeneic hematopoietic stem cell transplant (HSCT). The result is based on a significant reduction in CMV infection rates in a phase 3 study.
While the use of Jakafi (ruxolitinib) is firmly rooted in the treatment paradigm for patients with myelofibrosis, other novel agents, such as momelotinib and pacritinib are also gaining the interest of researchers in the field.
Older patients with acute myeloid leukemia (AML) often face a difficult choice: risky, intensive chemotherapy that offers a small chance of a cure versus non-intensive chemotherapy meant to improve physical comfort and quality of life.
In an interview with CURE, Ruben Mesa, M.D., director, UT Health San Antonio Cancer Center, shed light on these recent updates in PV and ET, and discussed the proper therapeutic management of these diseases.